ArticleActa pharmaceutica Sinica. B2023

Evolution and development of potent monobactam sulfonate candidate IMBZ18g as a dual inhibitor against MDR Gram-negative bacteria producing ESBLs.

Zhiwen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.